![](https://aardexgroup.com/wp-content/uploads/2024/07/Post-updated-300x169.png)
Breaking News
Clinical trial failures: Are we counting the cost of poor adherence?
Clearly it is in no one’s interests for a clinical trial to fail. Whenever these high-stake activites are abandoned and drug development pathways are aborted, missed opportunities abound. Beyond the sponsor’s missed commercial opportunity, there are missed opportunities to advance